Trinity Biotech Granted Extension to Meet Nasdaq Compliance
Trinity Biotech has until October 31, 2024, to meet the Nasdaq MVPHS requirement, securing a chance to maintain its listing.
- Latest
- Trending
Trinity Biotech has until October 31, 2024, to meet the Nasdaq MVPHS requirement, securing a chance to maintain its listing.
Amgen's Q2 profit drops due to higher expenses, but revenue sees a 20% increase, driven by Horizon acquisition.
Cathie Wood's ARK shifts focus, selling Ginkgo and Coinbase, while investing in 10X Genomics and Roku in a biotech-centered portfolio ...
America's crackdown on Chinese biotech could lead to drug shortages and higher costs, impacting patients without delivering promised security benefits.
"Fortress Biotech (FBIO) upgraded to 'Hold' by StockNews.com amid 5.8% decline; analysts offer mixed ratings as hedge funds increase stakes."
"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
Meatable, the cultivated meat market, plans to launch pork products in Singapore next year after a successful tasting event in ...
The first human to receive a Neuralink brain chip has been revealed as Noland Arbaugh, leading people to question if ...
Phase 1 biotech Boundless Bio raised $100 million at a $396 million market cap. Two IPOs are scheduled for the ...
Viva Biotech Holdings reported a 9.4% decrease in revenue and narrowed its net loss by 78% in FY 2023. Loss ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.